Rezolute/RZLT

$2.65

-1.11%
-
1D1W1MYTD1YMAX

About Rezolute

Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.

Ticker

RZLT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nevan Elam

Employees

51

Headquarters

Redwood city, United States
Website
www.rezolutebio.com

Rezolute Metrics

BasicAdvanced
$108M
Market cap
-
P/E ratio
-$1.11
EPS
1.21
Beta
-
Dividend rate
$108M
1.20801
$3.69
$0.72
344K
11.999
-45.04%
-48.79%
-47.75%
1.158
1.172
21.48%

What the Analysts think about Rezolute

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
264.91% upside
High $14.00
Low $7.00
$2.65
Current price
$9.67
Average price target

Rezolute Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$14M
-4.14%
Profit margin
0%
NaN%

Rezolute Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.74%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.25
-$0.28
-$0.27
-$0.34
-
Expected
-$0.36
-$0.28
-$0.30
-$0.30
-$0.28
Surprise
-29.78%
-0.88%
-10.99%
11.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rezolute stock?

Rezolute (RZLT) has a market cap of $108M as of May 16, 2024.

What is the P/E ratio for Rezolute stock?

The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of May 16, 2024.

Does Rezolute stock pay dividends?

No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of May 16, 2024.

When is the next Rezolute dividend payment date?

Rezolute (RZLT) stock does not pay dividends to its shareholders.

What is the beta indicator for Rezolute?

Rezolute (RZLT) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Rezolute stock price target?

The target price for Rezolute (RZLT) stock is $9.67, which is 264.91% above the current price of $2.65. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rezolute stock

Buy or sell Rezolute stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing